Bausch + Lomb unveils new ESCRS clinical data on enVista Aspire, LuxLife IOLs, ELIOS glaucoma procedure

Bausch + Lomb outlined new clinical study results slated for presentation at the ESCRS congress in London on Sept. 11-15.

Data focus on premium intraocular lenses, dry-eye drops, excimer laser glaucoma therapy, targeting outcomes such as vision quality, satisfaction, safety, effectiveness.

Real-world and multicenter studies suggest the company’s newer lenses delivered favorable visual and refractive performance with high patient-reported satisfaction.

Glaucoma procedure studies indicate sustained pressure-lowering benefit with an acceptable safety profile when used alone or alongside cataract surgery.

Management framed the program as a commercial push in Europe, supported by surgeon education and product demonstrations across its surgical portfolio.